Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Core Viewpoint - Lipocine Inc. has completed the final study visit in its Phase 3 clinical trial for LPCN 1154, an oral treatment for postpartum depression [1] Company Summary - Lipocine Inc. is a biopharmaceutical company focused on developing innovative products utilizing its proprietary technology platform for effective oral delivery [1] - The Phase 3 clinical trial for LPCN 1154 involved 90 patients diagnosed with severe postpartum depression [1] - The average baseline Hamilton depression rating scale (HAM-D) score for enrolled patients was 28.3, indicating a high severity of depression [1]